Epivario Inc.
Philadelphia, PA
- UEI
- M6ZTFQ3K1WT3
- CAGE
- 80GJ4
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 730 S 11th St, Philadelphia, PA 19147, USA
- Website
- epivario.com
- Founded
- 2017
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
About the company
Epivario Inc. is a for-profit corporate entity registered in the System for Award Management (SAM) since December 2017, with registration valid through June 2025. The company appears to be a biotechnology research organization focused on developing novel pharmacological interventions for substance use disorders, with a particular emphasis on exploring epigenetic regulators as potential treatments for addiction. Based on its federal grant awards, Epivario specializes in preclinical research and drug development, specifically targeting neurological mechanisms related to addiction memory and learning processes.
The company has secured multiple substantial federal grants from civilian agencies, primarily the National Institute on Drug Abuse (NIDA) and the National Institute on Alcohol Abuse and Alcoholism (NIAAA), totaling approximately $570,578 in research funding. These grants focus on developing innovative treatments for substance use disorders, including opioid use disorder (OUD), cocaine use disorder (CUD), and alcohol use disorder (AUD). Epivario's research centers on a novel approach involving the metabolic enzyme ACSS2, investigating how its inhibition can potentially disrupt drug-related memory consolidation and reduce addiction-related behaviors. The company's research methodology involves comprehensive screening of novel compounds, conducting in vitro and in vivo assays, evaluating pharmacological properties, and testing potential treatments in pre-clinical animal models to assess efficacy and potential side effects. Each grant represents a targeted investigation into a specific substance use disorder, with the overarching goal of developing new pharmacotherapeutic interventions for challenging addiction treatments.
Quick answers
Is Epivario Inc. registered in SAM.gov?
Yes. Epivario Inc.'s SAM.gov registration is active through July 24, 2027.
What is Epivario Inc.'s most recent federal award?
Epivario Inc.'s most recent federal grant award is Developing a novel epigenetic regulator as a treatment for opioid use disorder project summary/abstract opioid use… (R43DA058603), from National Institute on Drug Abuse (NIH), on September 30, 2024.
On GovTribe
See Epivario Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors